BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38452634)

  • 21. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
    Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
    Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genome-wide mutation analysis in precancerous lesions of endometrial carcinoma.
    Li L; Yue P; Song Q; Yen TT; Asaka S; Wang TL; Beavis AL; Fader AN; Jiao Y; Yuan G; Shih IM; Song Y
    J Pathol; 2021 Jan; 253(1):119-128. PubMed ID: 33016334
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intratumour heterogeneity in endometrial serous carcinoma assessed by targeted sequencing and multiplex ligation-dependent probe amplification: a descriptive study.
    Cuevas D; Velasco A; Vaquero M; Santacana M; Gatius S; Eritja N; Estaran E; Matias-Guiu X
    Histopathology; 2020 Feb; 76(3):447-460. PubMed ID: 31550396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues.
    Mutter GL; Monte NM; Neuberg D; Ferenczy A; Eng C
    Cancer Res; 2014 May; 74(10):2796-802. PubMed ID: 24662919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.
    Le Gallo M; Rudd ML; Urick ME; Hansen NF; Zhang S; ; Lozy F; Sgroi DC; Vidal Bel A; Matias-Guiu X; Broaddus RR; Lu KH; Levine DA; Mutch DG; Goodfellow PJ; Salvesen HB; Mullikin JC; Bell DW
    Cancer; 2017 Sep; 123(17):3261-3268. PubMed ID: 28485815
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Co-existing TP53 and ARID1A mutations promote aggressive endometrial tumorigenesis.
    Reske JJ; Wilson MR; Holladay J; Siwicki RA; Skalski H; Harkins S; Adams M; Risinger JI; Hostetter G; Lin K; Chandler RL
    PLoS Genet; 2021 Dec; 17(12):e1009986. PubMed ID: 34941867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens.
    Akahane T; Kitazono I; Yanazume S; Kamio M; Togami S; Sakamoto I; Nohara S; Yokoyama S; Kobayashi H; Hiraki T; Suzuki S; Ueno S; Tanimoto A
    BMC Med Genomics; 2020 Jul; 13(1):101. PubMed ID: 32652986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early-stage endometrial cancer, CTNNB1 mutations, and the relation between lymphovascular space invasion and recurrence.
    Imboden S; Tapia C; Scheiwiller N; Kocbek V; Altermatt HJ; Janzen J; Mueller MD; McKinnon B
    Acta Obstet Gynecol Scand; 2020 Feb; 99(2):196-203. PubMed ID: 31562818
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
    Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
    Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicoprognostical features of endometrial cancer patients with somatic mtDNA mutations.
    Semczuk A; Lorenc A; Putowski L; Futyma K; Bryk J; Miotla P; Bartnik E
    Oncol Rep; 2006 Nov; 16(5):1041-5. PubMed ID: 17016590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational profile of endometrial hyperplasia and risk of progression to endometrioid adenocarcinoma.
    Russo M; Newell JM; Budurlean L; Houser KR; Sheldon K; Kesterson J; Phaeton R; Hossler C; Rosenberg J; DeGraff D; Shuman L; Broach JR; Warrick JI
    Cancer; 2020 Jun; 126(12):2775-2783. PubMed ID: 32187665
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Detection of somatic mutations in peritoneal lavages and plasma of endometrial cancer patients: A proof-of-concept study.
    Mayo-de-Las-Casas C; Velasco A; Sanchez D; Martínez-Bueno A; Garzón-Ibáñez M; Gatius S; Ruiz-Miró M; Gonzalez-Tallada X; Llordella I; Tresserra F; Rodríguez S; Aldeguer E; Roman-Canal B; Bertran-Alamillo J; García-Peláez B; Rosell R; Molina-Vila MA; Matias-Guiu X
    Int J Cancer; 2020 Jul; 147(1):277-284. PubMed ID: 31953839
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.
    Cohen SA; Turner EH; Beightol MB; Jacobson A; Gooley TA; Salipante SJ; Haraldsdottir S; Smith C; Scroggins S; Tait JF; Grady WM; Lin EH; Cohn DE; Goodfellow PJ; Arnold MW; de la Chapelle A; Pearlman R; Hampel H; Pritchard CC
    Gastroenterology; 2016 Sep; 151(3):440-447.e1. PubMed ID: 27302833
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathologic and Genomic Analysis of
    Momeni-Boroujeni A; Dahoud W; Vanderbilt CM; Chiang S; Murali R; Rios-Doria EV; Alektiar KM; Aghajanian C; Abu-Rustum NR; Ladanyi M; Ellenson LH; Weigelt B; Soslow RA
    Clin Cancer Res; 2021 May; 27(9):2613-2623. PubMed ID: 33602681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CTNNB1 (beta-catenin) mutation identifies low grade, early stage endometrial cancer patients at increased risk of recurrence.
    Kurnit KC; Kim GN; Fellman BM; Urbauer DL; Mills GB; Zhang W; Broaddus RR
    Mod Pathol; 2017 Jul; 30(7):1032-1041. PubMed ID: 28281553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stratification of endometrioid endometrial cancer patients into risk levels using somatic mutations.
    Dai D; Thiel KW; Salinas EA; Goodheart MJ; Leslie KK; Gonzalez Bosquet J
    Gynecol Oncol; 2016 Jul; 142(1):150-157. PubMed ID: 27181389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status.
    Pappa KI; Choleza M; Markaki S; Giannikaki E; Kyroudi A; Vlachos G; Voulgaris Z; Anagnou NP
    Gynecol Oncol; 2006 Mar; 100(3):596-600. PubMed ID: 16256179
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PTEN mutations as predictive marker for the high-grade endometrial cancer development in slovak women.
    Gbelcová H; Gergely L; Šišovský V; Straka Ľ; Böhmer D; Pastoráková A; Sušienková K; Repiská V; Korbeľ M; Danihel Ľ; Priščáková P
    Physiol Res; 2022 Dec; 71(Suppl 1):S125-S135. PubMed ID: 36592448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Racial differences in oncogene mutations detected in early-stage low-grade endometrial cancers.
    Cote ML; Atikukke G; Ruterbusch JJ; Olson SH; Sealy-Jefferson S; Rybicki BA; Alford SH; Elshaikh MA; Gaba AR; Schultz D; Haddad R; Munkarah AR; Ali-Fehmi R
    Int J Gynecol Cancer; 2012 Oct; 22(8):1367-72. PubMed ID: 23013731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas.
    de Jonge MM; Auguste A; van Wijk LM; Schouten PC; Meijers M; Ter Haar NT; Smit VTHBM; Nout RA; Glaire MA; Church DN; Vrieling H; Job B; Boursin Y; de Kroon CD; Rouleau E; Leary A; Vreeswijk MPG; Bosse T
    Clin Cancer Res; 2019 Feb; 25(3):1087-1097. PubMed ID: 30413523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.